Montara Therapeutics
Montara Therapeutics is a preclinical-stage biopharmaceutical company focused on developing safer, more efficacious therapies for neurological diseases using its proprietary BrainOnly™ platform. The platform aims to enable brain-specific pharmacology, preventing peripheral toxicities and expanding druggable targets for CNS diseases. Supported by top-tier investors, Montara is committed to revolutionizing brain-targeted drug discovery and development.
Industries
Nr. of Employees
small (1-50)
Montara Therapeutics
San Francisco, California, United States, North America
Products
Brain‑selective pharmacology platform
A platform technology that enables brain‑restricted pharmacology by pairing a brain‑penetrant target‑specific small molecule (chimera) with a non‑brain‑penetrant peripheral blocker to prevent peripheral on‑target activity and concentrate drug activity in the CNS.
Brain‑selective pharmacology platform
A platform technology that enables brain‑restricted pharmacology by pairing a brain‑penetrant target‑specific small molecule (chimera) with a non‑brain‑penetrant peripheral blocker to prevent peripheral on‑target activity and concentrate drug activity in the CNS.
Services
Collaborative preclinical development and partnerships
Collaborative research and partnerships to develop brain‑selective therapeutics, including grant‑funded projects and participation in therapeutic exchange programs to advance target‑specific programs and biomarkers.
Preclinical pipeline advancement to IND
Internal preclinical development services to progress discovery programs toward IND and development candidate (DC) status, including in vivo proof‑of‑concept and IND‑enabling studies.
Collaborative preclinical development and partnerships
Collaborative research and partnerships to develop brain‑selective therapeutics, including grant‑funded projects and participation in therapeutic exchange programs to advance target‑specific programs and biomarkers.
Preclinical pipeline advancement to IND
Internal preclinical development services to progress discovery programs toward IND and development candidate (DC) status, including in vivo proof‑of‑concept and IND‑enabling studies.
Expertise Areas
- Brain‑targeted drug discovery
- CNS preclinical development and IND enabling
- Medicinal chemistry and small‑molecule warhead engineering
- Combination pharmacology for organ‑restricted activity
Key Technologies
- Brain‑restricted pharmacology
- Two‑component combination therapy design
- Brain‑penetrant small‑molecule chimeras
- Non‑brain‑penetrant peripheral blockers